Allogeneic transplantation is successful in a minority of patients with primary refractory acute leukemia (PRAL). An HLA-matched sibling donor (MSD) is available only in 30-40% of the patients, whereas a partially mismatched related donor (PMRD) is available for most. We compared the outcome of 24 MSD (median age 24 years) and 19 PMRD (median age 34 years; P = 0.04) allograft recipients with PRAL. All MSD patients received non-T cell-depleted marrow whereas all PMRD patients received partially T cell-depleted marrow. All evaluable PMRD patients and 90% of the evaluable MSD patients attained CR. Six patients in each group with recurrent/persistent disease died. Ten PMRD (3-year probability 70%) and 14 MSD (3-year probability 63%) patients died of treatment-related causes. At the last follow-up, three PMRD (18-50 months; 3-year probability 14%) and four MSD (20-166 months; 3-year probability 20%) patients were alive and well. We conclude that allogeneic transplantation is a viable therapeutic option for PRAL. PMRD transplantation is a reasonable alternative in patients with no MSD, and results in similar outcome. In terms of identifying a donor and harvesting cells, a PMRD transplant is significantly quicker than an unrelated donor transplant -a point of great practical importance in the setting of failed induction chemotherapy where time is of the essence.
acute leukemia do not achieve complete remission (CR). [1] [2] [3] [4] While intensive salvage regimens can result in CR in some of them, overall the long-term survival of this group of patients is very poor with death due to progressive disease or complications of chemotherapy. 5, 6 High-dose chemoradiotherapy with allogeneic hematopoietic stem cell transplantation results in achievement of CR in a substantial proportion of patients with primary refractory acute leukemia, and long-term survival of a minority of them. [7] [8] [9] [10] [11] This is probably the result of graft-versus-leukemia reactions. 12 The ideal allogeneic donor in this clinical situation (as in all others) is an HLA-identical sibling (matched sibling donor, MSD). For patients who do not have an HLA-identical sibling, the treatment options are limited because, unlike for patients in CR, autotransplantation is not an option. While allogeneic transplantation from an unrelated donor is a possibility, the time taken to find an unrelated donor may be too long with refractory, progressive acute leukemia. Bone marrow transplantation from an HLA-mismatched family donor (partially mismatched related donor, PMRD) has been shown to be a viable therapeutic option in patients with hematologic malignancies. 13, 14 PMRD transplantation is likely to be as rapidly accessible as that from an HLA-identical sibling. More importantly, such donors are available for almost all patients.
This retrospective study was undertaken to compare the outcome of PMRD and HLA-identical sibling transplantation in patients with primary refractory acute leukemia. Twenty of the 24 recipients of HLA-identical sibling grafts were included in a prior report 10 as were the PMRD transplant recipients with acute myeloid leukemia (AML).
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Patients and methods
Patients were treated at two different institutions. All MSD transplants were performed at the Royal Marsden Hospital, Surrey, UK, whereas all PMRD transplants were performed at the South Carolina Cancer Center, Columbia, South Carolina, USA. chemotherapy (each 4-week block of therapy was counted as one cycle in patients with acute lymphoblastic leukemia). However, patients were included if less than 50% clearance of malignant cells had been achieved from the marrow after one cycle of chemotherapy. The following patients were excluded: myelodysplastic syndrome (refractory anemia with excess of blasts or in transformation), or blast crisis of known myeloproliferative disorder. Patients who had been treated elsewhere and referred with the diagnosis of primary refractory disease were excluded if normalization of blood counts had been achieved at any time and if a bone marrow had not been done at that time to determine the remission status.
As Table 1 shows, the two groups were comparable except that the PMRD recipients were significantly older than the MSD recipients. The median time from diagnosis to transplantation was 1.5 months longer in the PMRD group (P = NS).
As Tables 2 and 3 show, the conditioning regimens were different as was the processing of the hematopoietic tissue. All MSD grafts were non-T cell depleted, whereas all PMRD grafts were partially depleted of T cells using techniques described previously. 13, 15 Total body irradiation was given in a single fraction from opposed 60 Co sources at a low rate to the MSD recipients, and in multiple fractions using a linear accelerator at a more rapid rate to the PMRD recipients.
All patients were treated in high-efficiency particulate air-filtered single rooms. Antibiotic prophylaxis and ther- Table 2 HLA-identical sibling transplants (n = 24) apy varied in accordance with prevalent practices and research programs at both sites. All research protocols were approved by the local institutional review boards. All patients and donors gave informed consent for the transplant. As far as possible, patients underwent diagnostic bone marrow examination 3-6 weeks post transplant to see if the disease was still active or if CR had been attained.
Results
Engraftment
All evaluable patients (surviving 3 weeks) in both groups engrafted, achieving 0.5 × 10 9 /l neutrophils. The myeloid engraftment was sustained and no late graft failures were seen.
Graft-versus-host disease
Acute GVHD (any grade) was seen in 21 of 23 MSD graft recipients surviving at least 3 weeks, and responded adequately to therapy in 19. Two patients died of progressive grade IV acute GVHD. Chronic GVHD was seen in five of the 12 patients alive beyond day 100. One of the five patients with chronic GVHD died as a result of it.
Grade I-II acute GVHD was seen in three of 17 PMRD graft recipients surviving at least 3 weeks, and responded adequately to therapy. Grade III-IV acute GVHD was not seen. Chronic GVHD was seen in two of 12 patients alive beyond day 100. One of the two patients with chronic GVHD died as a result of it.
Disease response
All patients surviving 4 weeks were considered evaluable for disease response (22 MSD and 16 PMRD). Twenty of 22 MSD recipients actually underwent marrow examination and 18 were found to have attained CR (90%). All 16 PMRD recipients underwent marrow examination and were found to be in CR (100%).
Treatment-related mortality
Fourteen of 24 MSD recipients died of treatment-related causes between 14 and 4632 days post-transplant (median 77). The patient dying almost 13 years after transplantation (progressive interstitial pneumonitis) was one of the three survivors from a previous report. 10 The causes of death were interstitial pneumonitis (n = 5), infections (n = 3), acute GVHD (n = 2), chronic GVHD (n = 1), multiorgan failure (n = 1), liver failure (n = 1), and adult respiratory distress syndrome (n = 1).
Ten PMRD recipients died of treatment-related causes between 1 and 735 days after transplantation (median 73). The causes of death were infections (n = 4), interstitial pneumonitis (n = 3), chronic GVHD (n = 1), pulmonary failure (n = 1), and adult respiratory distress syndrome (n = 1).
The actuarial probabilities of treatment-related mortality were similar for the two groups ( Figure 1) .
Relapse
Four MSD patients relapsed at 67-629 days (median 455). All four died of relapsed disease as did the two who did not attain CR post transplant. Interestingly, three of the four relapsing patients had developed acute GVHD and two had developed chronic GVHD. However, none had active GVHD at the time of relapse. The two patients with persistent disease post transplant did not attain CR despite developing acute and chronic GVHD.
Six PMRD recipients relapsed at 90-368 days (median 169). Four received infusions of donor leukocytes to generate graft-versus-leukemia but all six died of recurrent disease.
The actuarial probabilities of relapse were similar for the two groups (Figure 2) . 
Discussion
This study confirms once again that allogeneic hematopoietic stem cell transplantation can result in long-term survival of a minority of patients with primary refractory acute leukemia, [7] [8] [9] [10] [11] in addition to providing longer follow-up for some patients reported earlier in 1994. 10 The major aim of this analysis was to compare MSD and PMRD transplantation. PMRD transplantation is a far more complex procedure with treatment-related mortality rates that are considerably higher than MSD transplantation. With low-risk or standard-risk diseases, the outcome of the two procedures would be expected to be significantly different. However, with extremely high-risk patients such as this group, it would appear that the biology of the underlying disease (aggressive disease resulting in high relapse rates) and the difficult clinical situation (high toxicity because of repeated courses of chemotherapy followed by transplantation) dictate the prognosis rather than the nature of the procedure because the outcomes were essentially equivalent.
There are several drawbacks in this analysis: treatment at different sites, over different time periods, different conditioning regimens and different supportive care. However, we believe these do not distract from the general conclusion of this study -which is the equivalence of two rather different procedures under clinically difficult circumstances. This is practically relevant because HLA-identical sibling donors are available only for one-third of patients. However, most patients will have access to a haploidentical family donor. The advantage of PMRD transplantation over unrelated donor transplantation is the ready and rapid potential availability of the donor -a factor which is of critical importance in patients with refractory, progressive acute leukemia where time is of the essence.
It was interesting to note that the median diagnosis-totransplant interval was almost 1. months longer for PMRD transplantation compared with MSD. There are a number of possible reasons for this. Firstly, a number of patients allografted at the Royal Marsden Hospital came from its own Leukaemia Unit, 4 whereas all the PMRD patients were treated elsewhere and referred to South Carolina specifically for transplantation resulting in some delay. Secondly, extra time could have elapsed while contemplating a relatively risky procedure like a PMRD allograft. The biologic consequences of this are difficult to determine. More courses of chemotherapy during the longer interval could serve to undermine the outcome. On the other hand, longer survival prior to the transplant may represent selection of slightly better-risk patients. Our studies did not show any relationship between the diagnosis-to-transplant interval and the outcome (data not shown), possibly because of relatively small patient numbers.
Almost all MSD patients received marrow. We have shown recently that the use of blood-derived stem cells is superior to marrow in terms of reduced relapse as well as lower treatment-related mortality because of high CD34 + cell doses. 16, 17 It is possible that the outcome of MSD patients with refractory acute leukemia could now be superior to what has been reported here and in the literature. It is not known if the outcome of PMRD transplantation could improve in a similar fashion because the source of stem cells does not appear to have made any difference to the outcome of PMRD transplantation. 13, 14, [18] [19] [20] Based on these data we advocate the use of PMRD transplantation as the therapy of choice in patients with primary refractory acute leukemia who are eligible for allogeneic transplantation but do not have a suitable MSD. It is essential to attempt tissue-typing on the patient and family at the time of diagnosis. This information will be useful to identify potential HLA-matched or HLA-mismatched hematopoietic stem cell donors who can be used if there is failure of induction therapy. Tissue-typing becomes very difficult in patients who have had chemotherapy and have not recovered normal marrow function sufficiently.
In conclusion, a high proportion of patients with acute leukemia refractory to conventional induction therapy achieve CR after high-dose chemoradiotherapy and hematopoietic stem cell support from HLA-matched or mismatched family members. A small proportion become longterm disease-free survivors. Doing a transplant for inadequate response earlier rather than later if the patient's performance status is good may improve results by minimizing complications.
